​

Exagen (XGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

XGN Stock Forecast

Exagen (XGN) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $13.33, with a high of $15.00 and a low of $10.00. This represents a 11.45% increase from the last price of $11.96.

- $3 $6 $9 $12 $15 High: $15 Avg: $13.33 Low: $10 Last Closed Price: $11.96

XGN Stock Rating

Exagen stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

XGN Price Target Upside V Benchmarks

TypeNameUpside
StockExagen11.45%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks5.51%

Price Target Trends

1M3M12M
# Anlaysts245
Avg Price Target$15.00$13.00$11.40
Last Closing Price$11.96$11.96$11.96
Upside/Downside25.42%8.70%-4.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-8---8
Sep, 25-7---7
Aug, 25-7---7
Jul, 25-51--6
Jun, 25-51--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2025Canaccord Genuity$15.00$11.9625.42%25.42%
Oct 14, 2025KeyBanc$15.00$11.0435.87%25.42%
Jul 30, 2025Cantor Fitzgerald$10.00$8.6315.87%-16.39%
Jul 29, 2025KeyBanc$12.00$8.4542.01%0.33%
Nov 12, 2024Mark MassaroBTIG$5.00$2.7979.21%-58.19%
May 14, 2024Kyle MiksonCanaccord Genuity$5.00$1.64204.88%-58.19%
Nov 17, 2022BTIG$7.00$3.40105.88%-41.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2025KeyBancOverweightOverweighthold
Sep 11, 2025B. RileyBuyinitialise
Jul 30, 2025Cantor FitzgeraldOverweightOverweighthold
May 15, 2025UBSOverweightOverweighthold
May 07, 2025BTIGBuyBuyhold
Nov 12, 2024BTIGBuyBuyhold
Nov 12, 2024KeyBancSector WeightSector Weighthold
May 14, 2024Cantor FitzgeraldOverweightOverweighthold
Mar 22, 2023BTIGBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.32$-1.68$-2.77$-1.34$-0.83----
Avg Forecast$-1.44$-1.75$-2.71$-1.47$-0.89$-0.68$-0.45$-0.36$-0.14
High Forecast$-1.42$-1.73$-2.63$-1.41$-0.87$-0.53$-0.33$-0.35$-0.13
Low Forecast$-1.49$-1.81$-2.86$-1.64$-0.90$-0.82$-0.59$-0.40$-0.16
Surprise %-8.33%-4.00%2.21%-8.84%-6.74%----

Revenue Forecast

$35M $49M $63M $77M $91M $105M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$41.98M$48.30M$45.56M$52.55M$55.64M----
Avg Forecast$39.98M$47.30M$41.59M$50.32M$55.73M$66.40M$74.28M$82.90M$93.60M
High Forecast$40.90M$48.39M$43.37M$50.59M$60.82M$67.38M$76.05M$87.30M$102.15M
Low Forecast$39.51M$46.75M$40.72M$50.09M$54.09M$65.42M$72.50M$78.50M$90.85M
Surprise %5.00%2.12%9.55%4.44%-0.17%----

Net Income Forecast

$-55M $-44M $-33M $-22M $-11M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-16.69M$-26.85M$-47.39M$-23.69M$-15.12M----
Avg Forecast$-25.54M$-31.01M$-47.83M$-27.01M$-15.67M$-11.92M$-8.50M$-6.80M$-2.48M
High Forecast$-25.15M$-30.54M$-46.53M$-24.97M$-15.41M$-9.33M$-5.79M$-6.12M$-2.38M
Low Forecast$-26.31M$-31.94M$-50.50M$-29.04M$-15.94M$-14.51M$-10.35M$-7.12M$-2.77M
Surprise %-34.65%-13.41%-0.93%-12.29%-3.57%----

XGN Forecast FAQ

Is Exagen stock a buy?

Exagen stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Exagen is a favorable investment for most analysts.

What is Exagen's price target?

Exagen's price target, set by 7 Wall Street analysts, averages $13.33 over the next 12 months. The price target range spans from $10 at the low end to $15 at the high end, suggesting a potential 11.45% change from the previous closing price of $11.96.

How does Exagen stock forecast compare to its benchmarks?

Exagen's stock forecast shows a 11.45% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (5.51%).

What is the breakdown of analyst ratings for Exagen over the past three months?

  • October 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Exagen’s EPS forecast?

Exagen's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.68, marking a -18.07% decrease from the reported $-0.83 in 2024. Estimates for the following years are $-0.45 in 2026, $-0.36 in 2027, and $-0.14 in 2028.

What is Exagen’s revenue forecast?

Exagen's average annual revenue forecast for its fiscal year ending in December 2025 is $66.4M, reflecting a 19.34% increase from the reported $55.64M in 2024. The forecast for 2026 is $74.28M, followed by $82.9M for 2027, and $93.6M for 2028.

What is Exagen’s net income forecast?

Exagen's net income forecast for the fiscal year ending in December 2025 stands at $-11.921M, representing a -21.13% decrease from the reported $-15.115M in 2024. Projections indicate $-8.5M in 2026, $-6.8M in 2027, and $-2.475M in 2028.